No profile data available.
Krystal Biotech, Inc. (KRYS) is a healthcare company in the skin treatment pharmaceuticals industry, based in Pittsburgh, United States, with about 295 full-time employees.
It reported revenue of $389.13 million for fiscal year 2025, up 33.9% from fiscal year 2024, and net income of $204.83 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $119.22 million, up 24.1% from a year before. Its market capitalization was $9.82 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Krystal Biotech reported $389.13 million in revenue for fiscal year 2025, up 33.9% from $290.52 million in fiscal year 2024. In Q2 2026 revenue was $119.22 million.
$9.82 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Kymera Therapeutics, Inc. (KYMR), Oruka Therapeutics, Inc. (ORKA), Arcutis Biotherapeutics, Inc. (ARQT), Almirall, S.a. (ALMRY).